Reuters logo
BRIEF-Oncosec announces positive phase II data for Immunopulse IL-12 in combination with pembrolizumab
February 23, 2017 / 4:43 PM / 7 months ago

BRIEF-Oncosec announces positive phase II data for Immunopulse IL-12 in combination with pembrolizumab

Feb 23 (Reuters) - Oncosec Medical Inc

* Oncosec announces positive phase ii data demonstrating company’s Immunopulse IL-12 in combination with pembrolizumab increased response rates in anti-PD-1 non-responder melanoma patients

* Combination therapy continued to demonstrate a favorable safety profile and was well tolerated

* New data from combination therapy showed 48% best overall response rate

* Combination of Immunopulse IL-12 and pembrolizumab can convert “cold” tumors to “hot” tumors

* Expect to initiate immunopulse IL-12 in combination with pembrolizumab study later in 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below